Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Abbisko Cayman Limited ( (HK:2256) ) has issued an announcement.
Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, will present updated results from a Phase 2 study of irpagratinib in combination with atezolizumab for advanced hepatocellular carcinoma at the 2025 ESMO GI Congress. The study highlights the combination’s favorable safety and promising anti-tumor activity, particularly in FGF19+ HCC patients, indicating potential advancements in treatment options for this cancer type.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited, through its subsidiary Abbisko Therapeutics, operates in the pharmaceutical industry focusing on innovative cancer treatments. The company is developing irpagratinib, a highly-selective FGFR4 small molecule inhibitor, targeting advanced hepatocellular carcinoma (HCC) characterized by hyperactivation of the FGF19 signaling pathway.
Average Trading Volume: 6,459,189
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.33B
For a thorough assessment of 2256 stock, go to TipRanks’ Stock Analysis page.